Fangqiong Li

1.4k total citations
33 papers, 990 citations indexed

About

Fangqiong Li is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Complementary and alternative medicine. According to data from OpenAlex, Fangqiong Li has authored 33 papers receiving a total of 990 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 12 papers in Cellular and Molecular Neuroscience and 7 papers in Complementary and alternative medicine. Recurrent topics in Fangqiong Li's work include Neuroscience and Neuropharmacology Research (10 papers), Neurotransmitter Receptor Influence on Behavior (7 papers) and Natural Compounds in Disease Treatment (6 papers). Fangqiong Li is often cited by papers focused on Neuroscience and Neuropharmacology Research (10 papers), Neurotransmitter Receptor Influence on Behavior (7 papers) and Natural Compounds in Disease Treatment (6 papers). Fangqiong Li collaborates with scholars based in China, United States and Macao. Fangqiong Li's co-authors include Lin Lü, Yanqin Li, Yavin Shaham, Yan-Xue Xue, Wei Wang, Yingying He, Mei Zhao, Chunmei Xu, Ping Wu and Lifen Xue and has published in prestigious journals such as Journal of Neuroscience, Diabetes and Journal of Medicinal Chemistry.

In The Last Decade

Fangqiong Li

31 papers receiving 981 citations

Peers

Countries citing papers authored by Fangqiong Li

Since Specialization

Citations

This map shows the geographic impact of Fangqiong Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fangqiong Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fangqiong Li more than expected).

Fields of papers citing papers by Fangqiong Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fangqiong Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fangqiong Li. The network helps show where Fangqiong Li may publish in the future.

Co-authorship network of co-authors of Fangqiong Li

This figure shows the co-authorship network connecting the top 25 collaborators of Fangqiong Li. A scholar is included among the top collaborators of Fangqiong Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fangqiong Li. Fangqiong Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial 2025 ·The Lancet Respiratory Medicine ·Nanshan Zhong, Rong Qiu, Jie Cao, Yanming Huang, Hua Zhou, Xingxiang Xu, Jin‐Fu Xu, Huan Ye, Zhixian Yang, Lingyun Gao, Shen Yao, Zuke Xiao, (unknown), Dianjie Lin, Li Zhao, Hao Xiong, Xianming Zhang, Fangqiong Li, Wei‐jie Guan, James D. Chalmers, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	9
2	Extracts from petal of the Crocus sativus (saffron) possesses detoxification effects on acetaminophen induced liver injury by inhibiting hepatocyte apoptosis via regulating Nrf2/HO-1 signaling 2025 ·Fitoterapia ·Tan Jin, Fangqiong Li, Xin Zhang, Hongrui Zhu, Jin Liu, (unknown), Yang Zhang, Dingkun Zhang, (unknown), Yongmei Shen	0
3	Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China 2024 ·Diabetes ·(unknown), (unknown), Zhifeng Cheng, Zhiyong Li, Hongwei� Jiang, Fang Zhang, Yufeng Li, Wei Qiu, Song Lu, Junhang Tian, (unknown), Fangqiong Li, Danqing Li	5
4	A biweekly DPP ‐4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial 2024 ·Diabetes Obesity and Metabolism ·(unknown), Zhifeng Cheng, Yufeng Li, (unknown), Liping Li, Xinsheng Li, Junqing Zhang, Lingling Xu, Weihong Song, Fangqiong Li, Zhanhui Zhang, Lixin Guo	0
5	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, and Dose-Increasing Study on the Safety, Tolerability and PK/PD of Multiple Doses of HSK7653 by Oral Administration in Patients with Type 2 Diabetes Mellitus in China 2023 ·Diabetes Therapy ·Nan Bai, Jin Wang, (unknown), Leili Gao, Wei Cui, (unknown), Fangqiong Li, Linong Ji, Yun Cai	3
6	Computational ghost imaging based on negative film imaging 2023 ·Optik ·(unknown), Yuan Zhang, (unknown), Fangqiong Li, Yuanyuan Wu, Lei Wu, Dejian Zhang, Jiangtao Liu	1
7	Effect of a high‐fat and high‐calorie food on the pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy subjects 2023 ·Pharmacology Research & Perspectives ·(unknown), Huijuan Zhu, Rong Song, Mengqi Zhang, Fangqiong Li, (unknown), Wei Wang, Jingying Jia, Chen Yu, Yanmei Liu	2
8	Safety and effectiveness of HSK21542 for hemodialysis patients: a multiple ascending dose study 2023 ·Frontiers in Pharmacology ·Mingming Pan, (unknown), Li Zhou, Yan Xu, (unknown), Chao-Qing Wu, Changlin Mei, Zhanzheng Zhao, Dong Sun, Tianjun Guan, Qinkai Chen, Ming Shi, Hui Xu, (unknown), Fangqiong Li, Rui Yan, Bi‐Cheng Liu	5
9	A phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy Chinese subjects 2023 ·Frontiers in Pharmacology ·Qian Chen, Qingqing Wu, Rong Song, Yating Wang, Zhang Mengqi, Fangqiong Li, (unknown), Wei Wang, Jingying Jia, Chen Yu, Yanmei Liu	3
10	Development and validation of an HPLC coupled with tandem mass spectrometry method for the determination of HSK7653, a novel super long‐acting dipeptidyl peptidase‐4 inhibitor, in human plasma and urine and its application to a pharmacokinetic study 2023 ·Biomedical Chromatography ·(unknown), Shuai Yan, (unknown), Hongzhong Liu, Ling Song, Xueting Yao, Ji Jiang, Fangqiong Li, (unknown), Dongyang Liu, Pei Hu	2
11	Safety, Pharmacokinetics, and Pharmacodynamics of a Single Bolus of the γ-aminobutyric Acid (GABA) Receptor Potentiator HSK3486 in Healthy Chinese Elderly and Non-elderly 2021 ·Frontiers in Pharmacology ·Xiaojiao Li, De‐Ming Yang, Qianqian Li, Hong Wang, Meng Wang, Pangke Yan, Nan Wu, Fangqiong Li, Shiping Ma, Yanhua Ding, Jingrui Liu, (unknown), (unknown)	42
12	CENPE promotes glioblastomas proliferation by directly binding to WEE1 2020 ·Translational Cancer Research ·(unknown), Jianchao Wang, Jie Zhou, (unknown), Min Yang, Fangqiong Li, Meng Zhang	5
13	Determining the Clinical Value and Critical Pathway of GTPBP4 in Lung Adenocarcinoma Using a Bioinformatics Strategy: A Study Based on Datasets from The Cancer Genome Atlas 2020 ·BioMed Research International ·(unknown), Juan Wang, Jiayan Mao, Fangqiong Li, Wei Chen, Wei Wang	8
14	ITRAQ-Based Proteomics Analysis of Triptolide On Human A549 Lung Adenocarcinoma Cells 2018 ·Cellular Physiology and Biochemistry ·Fangqiong Li, Dong-Xiao Zhao, Suwen Yang, Juan Wang, Qin Liu, Xin Jin, Wei Wang	32
15	Combination treatment with triptolide and hydroxycamptothecin synergistically enhances apoptosis in A549 lung adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs and Akt signaling pathways 2015 ·International Journal of Oncology ·Guanmin Meng, Wei Wang, Kequn Chai, Suwen Yang, Fangqiong Li, Kai Jiang	56
16	Cannabinoid CB1 receptor antagonist rimonabant disrupts nicotine reward-associated memory in rats 2011 ·Pharmacology Biochemistry and Behavior ·Qin Fang, Fangqiong Li, Yanqin Li, Yan-Xue Xue, Yingying He, Jianfeng Liu, Lin Lü, Jishi Wang	24
17	Basolateral Amygdala Cdk5 Activity Mediates Consolidation and Reconsolidation of Memories for Cocaine Cues 2010 ·Journal of Neuroscience ·Fangqiong Li, Yan-Xue Xue, Jishi Wang, Qin Fang, Yanqin Li, Weili Zhu, Yingying He, Jianfeng Liu, Lifen Xue, Yavin Shaham, Lin Lü	69
18	Central Amygdala Extracellular Signal-Regulated Kinase Signaling Pathway Is Critical to Incubation of Opiate Craving 2008 ·Journal of Neuroscience ·Yanqin Li, Fangqiong Li, Xiaoyi Wang, Ping Wu, Mei Zhao, Chunmei Xu, Yavin Shaham, Lin Lü	135
19	Cannabinoid CB1 receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats 2008 ·European Journal of Pharmacology ·Fangqiong Li, Qin Fang, Yu Liu, Mei Zhao, Dapeng Li, Jishi Wang, Lin Lü	42
20	Effects of scopolamine and ketamine on reconsolidation of morphine conditioned place preference in rats 2008 ·Behavioural Pharmacology ·Haifeng Zhai, Ping Wu, (unknown), Fangqiong Li, Yu Liu, Lin Lü	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact